What's Happening?
A recent clinical trial conducted by Mass General Brigham has found that the wake-promoting drug solriamfetol (Sunosi) can significantly improve alertness in early-morning shift workers suffering from shift work disorder. This condition, characterized
by excessive sleepiness and disrupted sleep patterns, affects workers who start their shifts between 3 a.m. and 7 a.m., a time when the brain is naturally inclined to sleep. The study, published in NEJM Evidence, involved 78 participants who were divided into two groups: one receiving solriamfetol and the other a placebo. Over four weeks, those taking the drug reported reduced sleepiness and improved work performance. The trial addresses a previously unmet need, as no clinical trials had focused on early-morning shift workers, despite their prevalence.
Why It's Important?
The findings of this study are significant as they offer a potential solution to the challenges faced by early-morning shift workers, who are crucial to various industries yet often suffer from impaired job performance and safety risks due to sleep disorders. By improving alertness and reducing sleepiness, solriamfetol could enhance productivity and safety, benefiting both workers and employers. The study highlights the need for targeted treatments for different types of shift workers, acknowledging the biological challenges they face. This could lead to broader acceptance and use of such medications, potentially improving the quality of life for millions of workers.
What's Next?
Following the promising results of this trial, researchers are planning a follow-up study to test solriamfetol in overnight shift workers. This could pave the way for the drug's approval as a treatment for shift work disorder across various shift schedules. The long-term effects of solriamfetol still require further investigation, particularly in diverse populations and over extended periods. The outcome of these studies could influence regulatory decisions and healthcare practices, potentially leading to wider availability of effective treatments for shift work disorder.
